Grade II glioma

This study tests whether a targeted drug called selumetinib works as well as standard chemotherapy (carboplatin and vincristine) for children and young adults with a slow-growing brain tumor called low-grade glioma. Participants must be 2 to 21 years old and have a tumor without …

This early-stage trial tests two drugs—triapine and temozolomide—together in people whose glioblastoma has returned. The goal is to find the safest dose and see how well patients tolerate the combination. About 30 adults with recurrent grade 2-4 glioma will take part.

This study tests a daily pill called vorasidenib in 10 teenagers (ages 12 to 17) with a slow-growing brain tumor (grade 2 glioma) that has a specific genetic mutation (IDH1 or IDH2). The goal is to see if the drug is safe, how it affects growth and development, and whether it can…

This early-stage trial is testing the safety and best dose of two drugs, trametinib and everolimus, given together to children and young adults whose gliomas (a type of brain tumor) have come back after previous treatment. The study aims to find the highest dose that is safe and …

This study tests a more intense treatment for a fast-growing type of brain cancer called IDH wildtype glioma. It combines higher doses of radiation with the chemotherapy drug temozolomide to try to stop the tumor from growing longer. The trial will enroll 40 adults with this spec…

This early-phase trial is testing a new type of immunotherapy called anti-GARP CAR T-cell therapy for people with recurrent high-grade gliomas (aggressive brain tumors). Researchers will take a patient's own immune cells, modify them in the lab to target a protein called GARP fou…

This study tests whether a custom-made video, showing symptoms and side effects based on each patient's own brain scan, can lower anxiety for people with brain tumors and their caregivers during radiation treatment. About 117 patients with newly diagnosed glioma and their caregiv…

This study tests a remote cognitive rehabilitation program for adults with slow-growing brain tumors (grade 2 or 3 glioma) who often struggle with memory, attention, and thinking. About 187 participants will either receive the program or standard care. The goal is to see if the p…

This early phase 1 trial is testing an oral drug called DSP-0390 in 20 people with IDH-mutant gliomas who are scheduled for tumor removal surgery. The goal is to see how much of the drug gets into the brain tumor and blood, and whether it affects cholesterol-related pathways. Par…

This study tests a new type of MRI scan that uses a special substance (hyperpolarized 13C pyruvate) to see how brain tumors use energy. Researchers want to know if this scan is safe and can show changes in tumor metabolism over time. About 300 people with low-grade gliomas will b…

This study follows 150 adults with slow-growing IDH-mutant grade 2 gliomas who are taking vorasidenib after surgery. Researchers will track quality of life, seizures, and tumor response in routine German clinics. The goal is to see how well the drug works outside of strict trial …

This study looks at how electrical pulses used by surgeons during awake brain surgery affect the brain. Researchers will measure brain waves in 12 people with low-grade glioma before and after tumor removal. The goal is to better understand which brain networks are turned off by …